PRKDC and glioblastoma: Targeting such a signaling cascade with small-molecule inhibitors against DNA-PK reverses the TMZ resistance in clinically relevant recurrent PDX models, thus opening the possibility of clinical translation to overcome chemoresistance in GBM.